CRDF
Cardiff Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.89
−2.46%Oct 28, 2026, 07:09 UTC
Cardiff Oncology said Chief Medical Officer Roger Sidhu departed by mutual agreement effective October 22, 2026, and Leila Alland was appointed interim Chief Medical Officer effective October 23, 2026.
Oct 21, 2026, 20:05 UTC
The U.S. Food and Drug Administration granted orphan drug designation to Cardiff Oncology, Inc.’s onvansertib for treating chronic myelomonocytic leukemia.
Source:Sep 14, 2026, 13:32 UTC
Cardiff Oncology and Nerviano Medical Sciences signed a confidential settlement agreement on September 14, 2026 to dismiss their litigation with prejudice and exchange mutual releases, with no monetary payment or admission of liability.
Sep 14, 2026, 12:30 UTC
Cardiff Oncology and Nerviano Medical Sciences amended their 2017 exclusive license agreement.
Source:Aug 11, 2026, 20:10 UTC
Cardiff Oncology presented positive Phase 2 CRDF-004 data at ASCO supporting advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into a planned registrational program for first-line RAS-mutated metastatic colorectal cancer.
Source:Jul 15, 2026, 12:00 UTC
Cardiff Oncology entered into definitive agreements for a registered direct offering of shares of its common stock and warrants.
Source: